<DOC>
	<DOCNO>NCT01531829</DOCNO>
	<brief_summary>In select patient acute pulmonary embolism ( PE ) , low dose ( 50mg/2h ) recombinant tissue plasminogen activator ( rt-PA ) regimen report less bleeding tendency FDA-approved rt-PA 100mg/2h regimen 100mg/2h regimen ( 3 % vs.10 % ) , worthwhile reveal whether low dose rt-PA plus low molecular weight heparin ( LMWH ) rapidly reverse RV pressure overload PE , increase bleed adverse event . The aim study compare thrombolytic treatment LMWH patient acute normotensive PE right ventricular dysfunction ( RVD ) .</brief_summary>
	<brief_title>Low Dose Rt-PA Acute Normotensive Pulmonary Embolism With RVD</brief_title>
	<detailed_description>In acute pulmonary embolism ( PE ) , normotensive patient acute RV dysfunction echocardiography compute tomography myocardial troponin elevation may adverse outcome . Thrombolysis rapidly reverse RV pressure overload PE , increase possibility bleeding remain unclear whether may improve early long-term clinical outcome select normotensive patient . In previous study , find low dose ( 50mg/2h ) recombinant tissue plasminogen activator ( rt-PA ) regimen less bleeding tendency 100mg/2h regimen ( 3 % vs.10 % ) , worthwhile reveal whether low dose rt-PA plus Low Molecular Weight Heparin ( LMWH ) rapidly reverse RV pressure overload PE , increase bleed adverse event . In prospective , multicenter , randomize , control study , compare low dose rt-PA plus LMWH vs. LMWH alone acute normotensive pulmonary embolism patient RV dysfunction . The primary efficacy outcome composite death cause treatment failure , improvement right ventricular function echocardiogram pulmonary artery obstruction CT angiographs within 7 day randomization . Second efficacy outcome recurrence pulmonary embolism deep venous thrombosis . Safety outcomes include serious life threaten bleed cerebral hemorrhage major bleed episode , also include mild bleeding . In addition , 90-day clinical echocardiographic follow-up perform , recurrence pulmonary embolism deep venous thrombosis record . The study expect enroll approximately 460 patient . By determine benefit vs risk Low dose rt-PA plus LMWH compare LMWH alone treatment submassive intermediate-risk PE , trial expect reveal worth Low dose rt-PA plus LMWH treatment kind PE patient suitable thrombolysis .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . 18 y≤Age≤75y 2 . Acute PE ( first symptom occur 14 less randomization ) confirm lung scan , positive compute tomographic pulmonary angiogram , positive selective pulmonary angiogram 3 . Hemodynamic stability , diastolic pressure &gt; 90mmHg . 4 . RV dysfunction confirm echocardiography ( ≥1 criterion ) , except leftside heart disease , congenital heart disease mitral valve disease . Increase right ventricle show present RV enddiastolic anteroposterior diameter &gt; 25 mm , Right/left ventricular enddiastolic diameter &gt; 1 ( apical subcostal 4chamber view ) Right/left ventricular enddiastolic anteroposterior diameter &gt; 0.5 Hypokinesis RVfree wall ( range motion le 5 mm ) Tricuspid regurgitation pressure &gt; 30mmHg 1 . RV anterior wall thickness &gt; 5mm confirm echocardiography 2 . Active internal bleeding spontaneous intracranial hemorrhage precede 6 month 3 . Major surgery , organ biopsy noncompressible puncture within 2 week 4 . Ischemic stroke occur within 2 month 5 . Gastrointestinal bleeding within 10 day 6 . Severe trauma occur within15 day 7 . Neurosurgery eye surgery within 1 month 8 . Severe hypertension difficult control ( systolic blood pressure &gt; 180mmHg diastolic blood pressure &gt; 110mmHg ) 9 . Cardiopulmonary resuscitation 10 . Platelet count le 100×109 / L 11 . Pregnancy , within 2 week post partum 12 . Infective endocarditis ; leave atrial thrombus ; aneurysm 13 . Serious liver kidney dysfunction 14 . Diabetic hemorrhagic retinopathy 15 . Suffering bleed disorder 16 . Chronic thromboembolic pulmonary hypertension 17 . Moderate severe chronic obstructive pulmonary disease ( COPD ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>pulmonary embolism</keyword>
	<keyword>right ventricular dysfunction</keyword>
	<keyword>Thrombolysis</keyword>
	<keyword>Heparin</keyword>
</DOC>